rs10137103 - IGHVIII-67-4 - IGHV1-68
Magnitude 2.2 · 1 study on file
Reported associations
-
Genetic determinants of IgG antibody response to COVID-19 vaccination - Unknown journal (n.d.) · Unknown authors · PubMed 38181733
ABSTRACT: Summary Human humoral immune responses to SARS-CoV-2 vaccines exhibit substantial inter-individual variability and have been linked to vaccine efficacy. To elucidate the underlying mechanism behind this variability, we conducted a genome-wide association study (GWAS) on the anti-spike IgG serostatus of UK Biobank participants who were previously uninfected by SARS-CoV-2 and had received either the first dose (n = 54,066) or the second dose (n = 46,232) of COVID-19 vaccines. Our analysis revealed significant genome-wide associations between the IgG antibody serostatus following the initial vaccine and human leukocyte antigen (HLA) class II alleles. Specifically, the HLA-DRB1∗13:02 allele (MAF = 4.0%, OR = 0.75, p = 2.34e−16) demonstrated the most statistically significant
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Screening
-
COVID-19 antibody testing after vaccination Moderate
rs10137103 G-allele carriers show reduced anti-SARS-CoV-2 IgG response after first vaccine dose, warranting verification of immune response.
Obtain serum anti-SARS-CoV-2 spike protein IgG level 2-4 weeks after vaccination.